Integrated radio-theranostics using a [89Zr]Zr-/[177Lu]Lu-labeled B7-H3 antibody-drug conjugate for prostate cancer.
Yongkang Qiu, Tingfei Gu, Tianyao Wang...
https://pubmed.ncbi.nlm.nih.gov/42094601/Actively Recruiting
Led by Peking University First Hospital · Updated on 2026-08-19
16
Participants Needed
1
Research Sites
8 weeks
Total Duration
Researchers are evaluating a new imaging agent, a 68Ga-labeled B7-H3 nanobody, for immunoPET scans in patients with osteosarcoma, including those with relapsed or refractory disease. The study aims to assess the safety, feasibility, and diagnostic performance of this agent compared to conventional imaging and, when available, tissue analysis. B7-H3 is an immune checkpoint molecule highly present in osteosarcoma tumors but limited in normal tissues, making it a promising target for imaging. Participants will receive a single intravenous dose of the investigational 68Ga-B7-H3 nanobody, followed by PETCT imaging according to the study plan. The study will analyze how the tracer distributes in the body, how much it accumulates in tumors, and its ability to detect lesions. Safety will be monitored by tracking any adverse events related to the tracer. During the study, participants will undergo PETCT scans and safety assessments including monitoring for any side effects within about 30 days after imaging. Imaging results will be compared with standard scans and pathology findings when possible. The primary measures include lesion detection rates and safety outcomes, while secondary measures involve quantifying tracer uptake in osteosarcoma lesions. The study runs from April 2026 to September 2026, with participants aged 10 to 80 years.
CONDITIONS
68Ga-B7-H3 Nanobody ImmunoPET in Osteosarcoma
T
Tingfei Gu, M.D
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Peking University First Hospital
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit
Duration - Up to 1 day
Participants receive a single intravenous injection of the 68Ga-B7-H3 nanobody followed by PET/CT imaging. Safety and imaging data are collected for analysis.
1 visit
Duration - Approximately 30 days
Participants are monitored for any adverse events or safety concerns related to the imaging agent for about 30 days after the scan.
Follow-up visits or contacts as needed
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
DIAGNOSTIC
Number of Arms
1
Have more questions? Get in touch with our team for quick support
Yongkang Qiu, Tingfei Gu, Tianyao Wang...
https://pubmed.ncbi.nlm.nih.gov/42094601/Peking University First Hospital
Lead Sponsor